New review by Iba et al: Inflammatory #thrombosis is critical in the progression of sepsis. Other than cytokines & microvesicles, contact and short-range cellular communication systems play roles in the development of thromboinflammation. bit.ly/3QXiQpx Jerrold Levy, MD

Platelets can do much more than what we thought! frontiersin.org/articles/10.33…

Congratulations to Dr Robert Montgomery Versiti @BloodResearchWI Medical College of Wisconsin on receiving the American Society of Hematology (ASH) Henry M. Stratton Medal at the 2022 ASH Annual Meeting. ASH #ASH22 #VersitiResearch hematology.org/newsroom/press…

VBRI investigator Qizhen Shi and colleagues published in JTH. Title: Pre-existing anti-factor VIII immunity alters therapeutic platelet-targeted factor VIII engraftment following busulfan conditioning through cytotoxic CD8 T cells jthjournal.org/article/S1538-…

Gene therapy for hemophilia A has arrived in the US. U.S. Food and Drug Administration Approves BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia A prnewswire.com/news-releases/…

VBRI Investigator Qizhen Shi published in JTH: Platelet-targeted gene therapy induces immune tolerance in #hemophilia and beyond sciencedirect.com/science/articl…

Check out publication by VBRI investigators Qizhen Shi Qizhen Shi, Karin Hoffmeister Karin Hoffmeister, Hervé Falet Hervé Falet 🌻 in JTH: PACSIN2 regulates platelet integrin β1 hemostatic function. jthjournal.org/article/S1538-…

Natural peripheral tolerance processes to #platelets granule contents can be co-opted ▶️💊therapeutics. Platelet-targeted gene🧬 therapy, unique approach to deliver therapeutic protein and induce immune tolerance ⁉️ Qizhen Shi @BloodResearchWI shorturl.at/acixU

Our paper on PACSIN2 in JTH is now available online, and there are no sign-ups, registrations, or fees required until November 15th! authors.elsevier.com/a/1hpo05TuFxF4…

Congratulations! 🍾

The findings in our study revealed the other side of the coin - a novel anti-inflammatory role of platelets that contrasts the prevailing proinflammatory view.

Check out publication by VBRI Senior investigator Qizhen Shi Qizhen Shi and collaborators Anti-mCD20 in combination with α-mCXCL13 monoclonal antibody inhibits anti-FVIII antibody development in hemophilia… pubmed.ncbi.nlm.nih.gov/39067397/

Preconditioning is crucial for the success of #platelet gene 🧬therapy in primed model. Chen et al. evaluated clinically translatable alkylating agent-based regimens for platelet gene therapy of hemophilia A 🐭in presence of FVIII immunity. Qizhen Shi jthjournal.org/article/S1538-…

Montgomery Educational Symposium on Hemostasis (MESH) was a huge success thanks to the incredibly bright minds and warm hearts that gathered to honor ‘Montgomery, Milwaukee’s’ amazing career Versiti Blood Research Institute

🧪 Dr. Qizhen Shi and researchers at Versiti Blood Research Institute developed a novel binding assay using a recombinant αIIbβ3 headpiece to evaluate VWF-αIIbβ3 binding in plasma from 441 Zimmerman Program participants. 🩸 Haematologica | bit.ly/439oD4e

Thrilled to share our new paper in 🩸Haematologica! We developed a VWF-αIIbβ3 binding assay and a VWF-RGES mouse model revealing how this interaction stabilizes platelet plugs. Grateful to my team & Versiti Blood Research Institute collaborators! Read here: bit.ly/439oD4e

Our new paper is out in Blood! "The TFH/TFR pathway in FVIII immune responses in mice" 1) TFR cells have a dual role in regulating anti-FVIII responses 2) TFH/TFR axis is key to inhibitor development in hemophilia A [doi.org/10.1182/blood.…] #Hemophilia #Immunology #Blood

Qizhen Shi: Immune Regulation in Hemophilia—Insights from TFH/TFR Qizhen Shi hemostasistoday.com/insight/qizhen… #FVIIIHemophiliaA #HemostasisToday #ImmuneResponse #TFRCells #Medicine #Health